Inclusion Criteria:
* Female participants aged 20 to 60 years.
* Dry, normal, combination, or oily scalp type.
* Clinical diagnosis of telogen effluvium associated with the use of GLP-1 receptor agonists (semaglutide or tirzepatide), diagnosed by a dermatologist and confirmed by trichogram analysis.
* Hair length of at least 3 cm.
* Use of GLP-1 receptor agonists (semaglutide or tirzepatide) for at least 3 months prior to enrollment.
* Intact skin in the study area (scalp).
* Use of GLP-1 receptor agonists approved by ANVISA and commercially available in Brazil.
* Under regular medical supervision during the study period.
* Loss of at least 5% of initial body weight prior to enrollment.
* Willingness to maintain the same hairstyle, haircut, and hair care habits throughout the study.
* Willingness to comply with all study procedures and requirements.
* Ability to provide written informed consent.
Exclusion Criteria:
* Pregnancy, breastfeeding, postpartum period up to 6 months, or intention to become pregnant during the study.
* Scalp conditions or skin marks that may interfere with study assessments.
* Known allergy or hypersensitivity to any component of the investigational product or similar products.
* Active scalp disorders that could interfere with study evaluations, including scarring alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate-to-severe seborrheic dermatitis, or eczema.
* Use of nonsteroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizing agents, or immunosuppressants within 2 weeks before enrollment.
* Ongoing radiotherapy or chemotherapy treatment.
* Hair chemical procedures within 30 days prior to enrollment.
* Recent use or dose adjustment of medications known to induce telogen effluvium.
* Use of dietary supplements for hair loss within the previous 3 months.
* Use of hair loss treatments or hair cycle modulators (e.g., minoxidil, finasteride, dutasteride, spironolactone) within the previous 3 months.
* Hair transplantation within the previous 18 months.
* Use of topical dermatological products for therapeutic or specific cosmetic purposes on the study area (scalp), such as hair tonics, topical minoxidil, medicated lotions, or acid-based treatments, within 48 hours prior to study initiation.
* Initiation, discontinuation, or modification of hormone therapy within the previous 3 months.
* Uncontrolled systemic diseases, including diabetes, lupus, thyroid disorders, anemia, or documented iron deficiency.
* Bariatric surgery within the previous 12 months.
* Hair loss associated with COVID-19 infection within the previous 6 months.
* Hospitalization within the previous 6 months.
* Major physical or psychological stressors within the previous 3 months.
* Uncontrolled endocrine disorders.
* History or evidence of alcohol or substance abuse.
* Immunosuppression caused by medications or active diseases.
* Excessive sun exposure or artificial tanning within 15 days before the baseline visit.
* Participation in another clinical study.
* Investigator site staff or family members directly involved in the study.
* Any condition that, in the investigator's opinion, may compromise participant safety or study integrity.
